Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1200 participants.

Also called NCT02430350

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02430350
Other papers using this trial's data
  • Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial Stroke, 2021-03 DOI, PubMed 33588596

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02430350. Randomized; quadruple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Compound Edaravone Injection
Intervention (Drug)
Edaravone Injection
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02430350
Content hash
78b016e51246b513b74b13b11d0c42bf61bfebc126fac7496d52ddedbac4f173